Sanara MedTech Inc.

Background

Company Name	Sanara MedTech Inc.
Stock Symbol	SMTI

Submit Your Information

If you suffered a loss on your Sanara MedTech Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On November 11, 2025, after market hours, Sanara announced that it would be “discontinuing operations of [its Tissue Health Plus (“THP”) program] to improve its operating efficiency and reallocate resources to its core surgical business.” The following day, before market hours, Sanara released its third quarter 2025 financial results, reporting that its “net loss from discontinued operations . . . was $31.2 million,” which “includes a noncash asset impairment charge of $26.5 million . . . related to the discontinued operations of THP.”

On this news, Sanara’s stock price fell $6.93, or 24.7%, to close at $21.11 per share on November 12, 2025, thereby injuring investors.

Submit Your Information